Cargando…

Receptor Tyrosine Kinase-Targeted Cancer Therapy

In the past two decades, several molecular targeted inhibitors have been developed and evaluated clinically to improve the survival of patients with cancer. Molecular targeted inhibitors inhibit the activities of pathogenic tyrosine kinases. Particularly, aberrant receptor tyrosine kinase (RTK) acti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamaoka, Toshimitsu, Kusumoto, Sojiro, Ando, Koichi, Ohba, Motoi, Ohmori, Tohru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274851/ https://www.ncbi.nlm.nih.gov/pubmed/30404198 http://dx.doi.org/10.3390/ijms19113491

Ejemplares similares

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
por: Yamaoka, Toshimitsu, et al.
Publicado: (2017)

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury
por: Ohmori, Tohru, et al.
Publicado: (2021)

Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis
por: Ando, Koichi, et al.
Publicado: (2023)

Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis
por: Ando, Koichi, et al.
Publicado: (2021)

Nivolumab plus Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
por: Ando, Koichi, et al.
Publicado: (2020)

Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
por: Ando, Koichi, et al.
Publicado: (2021)

Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer—A Systematic Review and Network Meta-Analysis
por: Ando, Koichi, et al.
Publicado: (2020)

Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury
por: Yamaoka, Toshimitsu, et al.
Publicado: (2019)

Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
por: Ando, Koichi, et al.
Publicado: (2020)

Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

Up-regulation of Syndecan-4 contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells
por: Toba-Ichihashi, Yoko, et al.
Publicado: (2015)

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation
por: Nishihara, Shigetoshi, et al.
Publicado: (2022)

Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer
por: Oki, Yasunari, et al.
Publicado: (2010)

Receptor-Tyrosine-Kinase-Targeted Therapies for Head and Neck Cancer
por: Elferink, Lisa A., et al.
Publicado: (2011)

Phage-Displayed Peptides for Targeting Tyrosine Kinase Membrane Receptors in Cancer Therapy
por: Aloisio, Annamaria, et al.
Publicado: (2021)

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
por: Yamaoka, Toshimitsu, et al.
Publicado: (2020)

Recent developments in receptor tyrosine kinases targeted anticancer therapy
por: Raval, Samir H., et al.
Publicado: (2016)

ALK: a tyrosine kinase target for cancer therapy
por: Holla, Vijaykumar R., et al.
Publicado: (2017)

Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
por: Hojjat-Farsangi, Mohammad
Publicado: (2014)

Receptor Tyrosine Kinases as Therapeutic Targets in Rhabdomyosarcoma
por: Crose, Lisa E. S., et al.
Publicado: (2011)

Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
por: Pottier, Charles, et al.
Publicado: (2020)

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases
por: Stern, David F
Publicado: (2000)

Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme
por: Tilak, Manali, et al.
Publicado: (2021)

The Incidence and Management of Cancer-Related Anorexia During Treatment with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors
por: Takahashi, Shunji, et al.
Publicado: (2023)

Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies
por: Medves, Sandrine, et al.
Publicado: (2012)

Mechanisms of receptor tyrosine kinase activation in cancer
por: Du, Zhenfang, et al.
Publicado: (2018)

The Receptor Tyrosine Kinase AXL in Cancer Progression
por: Rankin, Erinn B., et al.
Publicado: (2016)

Flotillins in Receptor Tyrosine Kinase Signaling and Cancer
por: Banning, Antje, et al.
Publicado: (2014)

Receptor tyrosine kinases in carcinogenesis
por: Zhang, Xiao-Ying, et al.
Publicado: (2016)

Tyrosine Kinase Receptors in Oncology
por: Esteban-Villarrubia, Jorge, et al.
Publicado: (2020)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto, Ross A, et al.
Publicado: (2015)

Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
por: Qin, Shuang, et al.
Publicado: (2019)

Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies
por: Wei, Ying, et al.
Publicado: (2023)

Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors
por: Park, Hyunjung, et al.
Publicado: (2022)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004)

Inhibition of Virus-Induced Cytokine Production from Airway Epithelial Cells by the Late Addition of Budesonide
por: Homma, Tetsuya, et al.
Publicado: (2020)

New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors
por: Lin, Nancy U, et al.
Publicado: (2004)

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
por: Sierra, J Rafael, et al.
Publicado: (2010)

The role of RICTOR downstream of receptor tyrosine kinase in cancers
por: Jebali, Ahlem, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pnj003qjf4ae4upuk2jgu7ip5q